Plasma procurement and plasma product safety in light of the <scp>COVID</scp> ‐19 pandemic from the perspective of the plasma industry-Reference-Cited by-同舟云学术

Plasma procurement and plasma product safety in light of the COVID ‐19 pandemic from the perspective of the plasma industry

Published:2022-03-17 Issue:6 Volume:117 Page:780-788
ISSN:0042-9007
Container-title:Vox Sanguinis
language:en
Short-container-title:Vox Sanguinis

Author:

Turecek Peter L.¹^ORCID,Hibbett Deborah²,Kreil Thomas R.³

Affiliation:

1. Plasma‐Derived Therapies R&D Baxalta Innovations GmbH, part of Takeda Vienna Austria

2. Global Communications and Public Affairs Takeda Pharmaceutical Company Limited Zurich Switzerland

3. Global Pathogen Safety Takeda Manufacturing Austria AG Vienna Austria

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/vox.13267

Reference72 articles.

1. Changes in Purchases for Intensive Care Medicines During the COVID-19 Pandemic

2. Managing medication supply chains: lessons learned from Taiwan during the COVID‐19 pandemic and preparedness planning for the future;Kuo S;J Am Pharm Assoc,2003

3. The impact of COVID ‐19 outbreak on the Transfusion Medicine Unit of a Northern Italy Hospital and Cancer Centre

4. Lessons learned in the collection of convalescent plasma during the COVID‐19 pandemic

5. Factors driving availability of COVID ‐19 convalescent plasma: Insights from a demand, production, and supply model

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stepwise options for preparing therapeutic plasma proteins from domestic plasma in low‐ and middle‐income countries;Vox Sanguinis;2023-10-23

2. The impact of the COVID‐19 pandemic on source plasma donations;Journal of Clinical Apheresis;2023-08-22

3. Parameters Associated with the Required Drug Dose of Intravenous Immunoglobulin in Stable Chronic Inflammatory Demyelinating Polyradiculoneuropathy;Neurology International;2023-03-10

4. The Evolution of the Safety of Plasma Products from Pathogen Transmission—A Continuing Narrative;Pathogens;2023-02-15

5. Evaluation of immunoglobulin replacement therapy in secondary immunodeficiency at three British Columbia hospitals;Vox Sanguinis;2023-01-30